Battle Over US FDA’s ‘Intended Use’ Rule Continues
Executive Summary
PhRMA and Pfizer attorneys criticize the rule’s broad evidence standard, lack of safe harbors, and disregard of the First Amendment. Opposition to the rule is expected to continue to play out in lawsuits.